At a recent meeting of the San Francisco AIDS Foundation that took place at the San Francisco Department of Public Health, Oscar Bacon led a discussion about a new AIDS prevention pill. Bacon is the lead clinician for the San Francisco Clinic that is now seeking volunteers for the first demonstration trial of Truvada, produced by Gilead Sciences, Inc. Truvada is the first pill ever to block HIV before it strikes. Enrollment was opened on September 21 for 300 potential volunteers in the study. The study will examine how the drug will be received by people who are, so far, uninfected, but are at high risk. Recruiters are seeking study volunteers including transgender females and men who have sex with men (MSM). Participants will receive 48 weeks of the drug at no cost, in exchange for regular monitoring of their social habits and tests that will assess the pill’s effectiveness in preventing transmission of the virus.
Date of Publication
Disclaimer: NPIN provides this information as a public service only. The views and information provided about the materials, funding opportunities, and organizations do not necessarily state or reflect those of the U.S. Department of Health and Human Services, CDC, or NPIN.